H uman high-affinity IgE receptor (FcRI) exists in two isoform, a tetramer containing the ␤ chain FcRI-␣␤␥ 2 and a trimer lacking the ␤ chain FcRI-␣␥ 2 , depending on cell type. 1 The FcRI-␤ gene (MS4A2) has been recognized as an atopyrelated gene, initially discovered from a genetic linkage study 2 and also from a genetic association study 3 by our group, and the functional roles of FcRI-␤ protein have been investigated extensively. For example, the FcRI-␤ chain mediates intracellular signaling through the immunoreceptor tyrosine-based activation motif and is phosphorylated in response to antigen cross-linking of the receptor-bound IgE. 1 The human FcRI-␤ chain acts as an amplifier for mast cell activation and cell surface expression of FcRI. 4, 5 Although the existence of the FcRI-␣␤␥ 2 and FcRI-␣␥ 2 receptor subtypes has been reported, 6 there has been no direct evidence of these two subtypes of FcRI in vivo at the protein level. Furthermore, the precise pathophysiological roles of the FcRI-␤ chain in human atopic diseases remain unclear. Recently, we raised an antibody against human FcRI-␤ that was useful for the in situ detection of the FcRI-␤ protein. 7 Atopic keratoconjunctivitis (AKC) 8, 9 and vernal keratoconjunctivititis (VKC) 10 are the most severe forms of chronic allergic conjunctivitis. Massive infiltration of mast cells occurs, and serum and tear IgE levels are significantly higher than in healthy controls. 8, 11, 12 In addition, AKC and VKC tend to form giant papillae at the upper tarsal conjunctiva. 8, 10, 13 We resected giant papillae for therapeutic purposes 14 and carried out histopathologic analysis with the resected tissues using our newly generated anti-FcRI-␤-specific antibody. We reported previously that IgE-bearing FcRI-␣ ϩ mast cells were increased in the giant papillae of patients with VKC 15 ; however, the expression of FcRI-␤ has yet to be evaluated. We found preferential FcRI-␤ expression in the mast cells of giant papillae samples compared with those of the control conjunctivae.
MATERIALS AND METHODS

Antibodies
Rabbit antiserum against unique C-terminal sequences of human FcRI-␤ (CYSELEDPGEMSPPIDL) was generated and the antiserum was purified on a protein-A column, as previously described. 7 Because this antibody was raised against the C-terminal region of human FcRI-␤ protein, it did not recognize the truncated form of FcRI-␤ protein described previously. 16 Other antibodies used in this study included Alexa 488 -conjugated-goat anti-rabbit-F(abЈ) 2 and Alexa 594 -conjugated goat anti-mouse IgG-F(abЈ) 2 (Invitrogen, Carlsbad, CA), Cy5-conjugated goat anti-mouse IgG1 antibody (Southern Biotechnology, Birmingham, AL), rabbit anti-FcRI-␥ polyclonal antibody (Upstate Biotechnology, Lake Placid, NY), phycoerythrin (PE)-conjugated mouse anti-FcRI-␣ monoclonal antibody (clone CRA1; e-bioscience, Tokyo, Japan), mouse anti-chymase monoclonal antibody (clone CC1; LAB Vision, Fremont, CA), mouse anti-CD1a monoclonal antibody
AKC/VKC Patient Selection and Giant Papillae Tissue Processing
Giant papillae were resected for therapeutic purposes 14 from six patients with AKC and four patients with VKC after obtaining informed consent (Table 1) .AKC was defined as bilateral, chronic inflammation of the conjunctiva and lids associated with atopic dermatitis, and VKC was defined as bilateral, chronic inflammation of the conjunctiva associated with predisposition to atopy. 18 Patients who had atopic dermatitis or corneal stromal neovascularization were excluded from the VKC diagnosis. All patients with AKC or VKC were treated by topical dexamethasone eyedrops for at least 4 weeks before surgery. Some patients were also treated by an oral steroid (20 mg/day prednisolone) or by cyclosporine A eyedrops. Total serum IgE concentration and specific IgE titer against 26 common antigens (including house dust mite and Japanese cedar pollen) were measured by SRL, Inc. (Tokyo, Japan) using the fluorescence enzyme immunoassay method and the enzyme-linked immunosorbent assay (ELISA) method, respectively. Upper bulbar conjunctivae were resected from six patients with conjunctivochalasis and four patients with superior limbic keratoconjunctivitis (SLK) 19 for therapeutic purposes after informed consent was obtained ( Table 2 ). Conjunctivochalasis was defined as a redundant conjunctiva typically located between the globe and the lower eyelid, 20 and SLK was defined according to the original clinical descriptions by Theodore. 21 Giant papillae were fixed with 4% paraformaldehyde (PFA)-phosphate buffered saline (PBS) for at least 4 hours and were then immersed in a 20% sucrose-PBS solution for 30 minutes, rapidly frozen in OCT compound (Sakura Finetek, Tokyo, Japan), and stored at Ϫ80°C. All procedures were approved by the ethics committee of Kyoto Prefectural University of Medicine, and the study was conducted in accordance with the tenets of the Declaration of Helsinki.
Immunohistochemical Analysis of Giant Papillae
Seven-micrometer cryostat sections were made from the specimens and air dried. Sections were then postfixed with 4% PFA-PBS. After blocking with 1% bovine serum albumin (BSA) in PBS, the slides were reacted with anti-FcRI-␤ or with anti-FcRI-␥ polyclonal antibodies for 1 hour and then with Alexa 488-conjugated anti-rabbit IgG antibody for 30 minutes. For double-staining with anti-tryptase, antiFcRI-␣, anti-basophil, or anti-CD1a monoclonal antibodies, the slides were incubated simultaneously with FcRI-␤ or FcRI-␥ polyclonal antibodies and with one of the monoclonal antibodies. In the case of double immunostaining with the anti-chymase antibody, the slides were incubated with the anti-chymase antibody overnight at 4°C, and then the FcRI-␤ polyclonal antibody was added and further incubated for 1 hour at room temperature. Alexa 488 -conjugated anti-rabbit IgG antibody and Alexa 594 conjugated anti-mouse IgG antibody were mixed and applied simultaneously as second antibodies. For triple immunostaining using the CD1a (class, mouse IgG1), FcRI-␣ (class, mouse IgG2a), and FcRI-␤ antibodies, the slides were incubated with the CD1a antibody and the FcRI-␤ antibody for 1 hour at room temperature. After PBS washes, Alexa 488-anti-rabbit IgG antibody, Cy5-anti-mouse IgG 1 antibody, and PE-anti-FcRI-␣ (class, mouse IgG2a) were applied simultaneously for another hour. As negative controls, normal rabbit IgG (Santa Cruz Biotechnology) was used instead of the FcRI-␤ polyclonal antibody at the same concentration, or the FcRI-␤ IgG antibodies were preabsorbed with a fivefold excess amount of the peptide used for immunization. These slides were then visualized with a confocal laser scanning microscope (FV1000; Olympus Corp., Tokyo, Japan).
A B FIGURE 1. Anti-FcRI-␤ immunostaining of giant papillae. Immunohistochemical staining was carried out with giant papillae specimens from patients with AKC or VKC using the anti-FcRI-␤ antibody (A) and control rabbit IgG (B) at the same concentration. Original magnification, 200ϫ. This is representative data obtained from 1 of 10 patients (patient 5 in Table 1 ). 
Cell Counting
Numbers of FcRI-␤ ϩ and FcRI-␣ ϩ cells (membrane staining) and tryptase ϩ cells (intracellular staining) were counted manually using 200ϫ magnification immunostaining images. Positive cells, both in the epithelium and in the substantia propria, were counted per 1-mm unit length of the conjunctival surface as total. We counted three sections per each patient for FcRI-␤ immunostaining and two sections for the remaining staining. All immunostained sections were evaluated by an observer who was blinded to the clinical data of the patients. We carried out two independent series of cell staining and counting, and we showed one representative result.
RESULTS
FcRI-␤ Immunostaining of Giant Papillae and Control Conjunctivae
All the tested giant papillae samples (n ϭ 10; Table 1) showed focal-positive immunostaining in the epithelium and in the substantia propria with anti-FcRI-␤ (Fig. 1A) , and the negative-control slide stained by normal rabbit IgG (Fig. 1B) and by the preabsorbed FcRI-␤ antibody (data not shown) did not show any positive staining. In addition to anti-FcRI-␤ staining ( Fig. 2A) , all the tested giant papillae showed positive staining with anti-FcRI-␣ antibodies (Fig. 2B) ; there were FcRI-␣/ FcRI-␤ double-positive and FcRI-␣ single-positive cells (Fig.  2C ). Double-immunohistochemical staining of the nearby section shown in Figure 2A with anti-FcRI-␥ antibodies (Fig. 2D ) and with anti-FcRI-␣ antibodies (Fig. 2E) showed that all the FcRI-␣ ϩ cells were also FcRI-␥ ϩ (Fig. 2F) . Control upper bulbar conjunctivae from the conjunctivochalasis or SLK patients (n ϭ 10; Table 2 ) showed a few FcRI-␣ ϩ cells (Figs. 3A,  3C ) or a few tryptase-positive mast cells (Figs. 3B, 3D ) in its substantia propria but a negligible number of FcRI-␤ ϩ cells ( Fig. 3D; Table 3 ).
Immunolocalization and Quantification of FcRI-␤ ؉ Cells in Giant Papillae
The giant papillae were also double immunostained with antiFcRI-␤ and the antibodies to typical mast cell proteases (tryptase and chymase). FcRI-␤ immunostaining was observed at the cell periphery of the tryptase ϩ cells (Figs. 4C, 4G) . Some of the tryptase ϩ cells were FcRI-␤ negative ( Fig. 4C, 4G ; (Fig.  4I, asterisks) . We quantified the number of FcRI-␤ ϩ cells, FcRI-␣ ϩ cells, tryptase ϩ cells, and FcRI-␤/tryptase doublepositive cells. The numbers of FcRI-␤ ϩ , FcRI-␣ ϩ , and tryptase ϩ cells were significantly higher in the giant papillae than in the control conjunctivae ( Table 3 ). The ratio of the FcRI-␤ ϩ cells/FcRI-␣ ϩ cells in the giant papillae samples was 0.69 Ϯ 0.08 (mean Ϯ SD). That ratio was significantly higher than the ratio of the control samples (0.07 Ϯ 0.16). Of tryptase ϩ cells, 81% Ϯ 13% expressed FcRI-␤, a rate also significantly higher than that of the control samples. Samples with hypertrophic epithelium showed FcRI-␤ ϩ cells predominantly at the epithelial layers (Figs. 4A, 4D 
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FcRI-␤ Expression in the Basophils of Giant Papillae Tissues but Not in Langerhans Cells (LCs)
During immunohistochemical analysis we found some tryptase Ϫ -FcRI-␤ ϩ cells in the giant papillae sections, so we Table  1 ).
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IOVS, June 2009, Vol. 50, No. 6 speculated that the FcRI-␤ ϩ cells included basophils. Positive basophil staining was observed at the substantia propria of the giant papillae (Fig. 6A) . Double immunostaining using antiFcRI-␤ and anti-basophil antibodies showed FcRI-␤ immunostaining (green) at the periphery of the basophil (red) (Fig.  6C) . To examine the FcRI-receptor subtype in LCs of the giant papillae, immunostaining with CD1a and FcRI-␣/FcRI-␤ antibodies was carried out. Double-staining did not reveal any CD1a ϩ /FcRI-␤ ϩ cells (Figs. 7A, 7C, 7E ). On the other hand, two CD1a ϩ cells were FcRI-␣ ϩ cells (Figs. 7B, 7C, 7D ; arrows). By triple-immunohistochemical staining, we confirmed the existence of FcRI-␣ ϩ /CD1a ϩ /FcRI-␤ Ϫ LCs (Fig. 7E , arrow) and of FcRI-␣ ϩ /FcRI-␤ ϩ /CD1a Ϫ mast cells (Fig. 7E,  arrowhead) .
DISCUSSION
To the best of our knowledge, this study is the first to demonstrate the existence of both FcRI-␣␤␥ 2 and FcRI-␣␥ 2 receptor subtypes in the giant papillae of patients with chronic allergic conjunctivitis. FcRI-␤ staining (Figs. 1, 2) showed a membranous staining pattern at the giant papillae. This staining pattern is consistent with our previous in vitro study using cultured human mast cells. 7 FcRI-␣ staining of the same slide showed a broader expression at the conjunctiva than that of FcRI-␤ (Fig. 2C) , and all the FcRI-␣ ϩ cells were FcRI-␥ ϩ (Fig. 2F ). These findings showed the existence of FcRI-␣␤␥ 2 mast cells and FcRI-␣␥ 2 mast cells in the giant papillae. In our previous study, we quantified FcRI-␤ protein expression in human mast cells using flow cytometry. 7 We found monophasic rather than biphasic FcRI-␤ expression pattern in human mast cells, 7 and Western blotting showed that the sensitivity of the FcRI-␤ antibody is approximately 100 pg in the recombinant FcRI-␤ protein (Matsuda A, unpublished data, 2008) . These results suggested that there are various levels of FcRI-␤ expression in each mast cell, and we identified an area of the mast cell population that expresses the FcRI-␤ protein past the threshold as FcRI-␤-positive cells. We could not deny the possibility that FcRI-␣␤␥ 2 and FcRI-␣␥ 2 receptor subtypes could be coexpressed in one mast cell. Nevertheless, we could conclude that there were at least two types of mast cells dominated by FcRI-␣␤␥ 2 or by FcRI-␣␥ 2 receptors. We further examined FcRI-␤ expression in the conjunctivae of two nonatopic conjunctival diseases as controls. We selected patients with conjunctivochalasis because relatively large upper bulbar conjunctivae samples could be obtained at the time of surgery. We examined patients with SLK as controls for two reasons: because an increased number of mast cells has been reported in the SLK conjunctivae 24 and to avoid bias from the very low number of the mast cells in the conjunctivochalasis samples. In addition, we excluded allergic conjunctivitis by careful slitlamp examinations in these cases. The increased number of FcRI-␤ ϩ cells and the higher ratio of FcRI-␤ ϩ /FcRI-␣ ϩ cells number in giant papillae samples suggested the preferential expression of FcRI-␤ protein in chronic allergic conjunctivitis. Double immunohistochemical staining with anti-FcRI-␤ and anti-tryptase/anti-chymase antibodies showed that 81% of tryptase ϩ cells were FcRI-␤ ϩ , and all the chymase ϩ cells were FcRI-␤ ϩ (Figs. 4, 5 ; Table 3 ). The FcRI-␤ ϩ rate among chymase-positive mast cells was higher than it was among among tryptase-positive mast cells; the reason for this is unknown and requires further investigation. During the analysis of double immunostaining with anti-FcRI-␤ and anti-tryptase antibodies, we found the preferential localization of FcRI-␤ ϩ mast cells within and around hypertrophic or convoluted epithelium and epithelial pseudotubules (Figs. 4, 5) . It was reported that antigen challenge in sensitized animals induced mast cell infiltration in esophageal epithelium. 25 Kitaura et al. 26 reported that a combination of antigen and IgE could stimulate mast cell migration by autocrine/paracrine secretion of chemokines. They also showed that Lyn, a signal transduction molecule associated with FcRI-␤ immunoreceptor tyrosine-based activation motif, 27 plays an essential role for the antigen-IgE-induced mast cell migration. We considered the possibility that the accumulation of FcRI-␤ ϩ mast cells in the hypertrophic epithelium could be a reflection of increased antigen stimulation at the ocular surface of AKC/VKC eyes. Furthermore, Galli et al. 28 reported that mast cells could induce airway epithelial cell proliferation in mouse asthma models in response to antigen stimulation; hence, it is possible that the infiltrating FcRI-␤ ϩ mast cells themselves play some roles in epithelial hypertrophy. This is the first study to show the existence of FcRI-␣␤␥ 2ϩ basophils (Fig. 6 ) and FcRI-␣␥ 2 ϩ LC (Fig. 7) at the protein level in giant papillae. Recently, it was reported that basophils play major roles in delayed-phase allergic reaction, independently of T cells and mast cells. 29 We are now investigating the role of FcRI-␤ ϩ basophils in the pathophysiology of AKC/ VKC. The existence of FcRI-␣␥ 2 ϩ LC is consistent with previous findings in mRNA levels, 30 and FcRI-␣␥ 2 ϩ LCs play important roles for enhanced antigen presentation in atopic disorders.
Recent studies have also indicated that the role of the FcRI-␤ protein in mast cells depends on the amount of IgEspecific antigen, with the low concentration of antigen FcRI-␤ chain working as an amplifier 31 but with a supraoptimal amount of antigen FcRI-␤ chain acting as an inhibitory molecule for degranulation and cytokine expression. 31, 32 In this study we showed preferential FcRI-␤ expression in the giant papillae samples in AKC/VKC, suggesting the involvement of an FcRI-␤-mediated mechanism for amplifying reactions against chronic low concentration of antigens. Additional functional studies will be necessary for investigating the roles of the FcRI-␤ chain; this antibody will be a useful tool for in situ analysis. 
